Published: 30 March 2021
Author(s): Ji Hyun Lee, Beom Kyung Kim, Soo Young Park, Won Young Tak, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Dong Hyun Sinn, Seung Up Kim
Issue: July 2021

Whether entecavir (ETV) or tenofovir disoproxil fumarate (TDF) affords the better prognosis after curative treatment of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) remains unclear. We compared recurrence and death rates between patients taking ETV and those taking TDF.

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness